Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05813561
Other study ID # DW_DWP14012306
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 30, 2021
Est. completion date February 17, 2023

Study information

Verified date April 2023
Source Daewoong Pharmaceutical Co. LTD.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.


Recruitment information / eligibility

Status Completed
Enrollment 332
Est. completion date February 17, 2023
Est. primary completion date July 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects must meet all of the following inclusion criteria to be eligible for this study: 1. Male or female subjects aged 18-75 years (inclusive); 2. Subjects with a confirmed diagnosis of reflux esophagitis (Grade A-D according to LA classification) by esophagogastroduodenoscopy (EGD) at our site within 7 days prior to Visit 2 (date of randomization). 3. Able to understand the information provided and to comply with protocol requirements; 4. Voluntarily agreed to participate in this clinical study and signed the informed consent form (ICF). Exclusion Criteria: - 1)Subjects who were allergic to the investigational drug and any of its components or esomeprazole magnesium enteric-coated tablets, other benzimidazole compounds and their components; 2)Subjects who were unable to undergo esophagogastroduodenoscopy (EGD); 3)Subjects with eosinophilic esophagitis, Barrett's esophagus (= 3 cm), gastroesophageal varices, stricture of oesophagus, active peptic ulcer, active upper/lower gastrointestinal bleeding, or malignancies confirmed by EGD; 4)Subjects with Zollinger-Ellison syndrome, achalasia, irritable bowel syndrome, or inflammatory bowel disease; 5)Subjects with concomitant diseases that may affect esophageal motility (e.g., dermatosclerosis, viral infection or fungal infection, etc.), or a history of esophageal radiotherapy or esophageal cryotherapy; 6)Subjects who had undergone surgery to reduce gastric acid secretion, or any surgery that affected the structure or function of the esophagus, stomach, or duodenum (excluding benign tumor excision, endoscopic resection of benign polyps, and simple suture procedures such as gastric perforation); 7)Subjects with warning symptoms (e.g., odynophagia, severe dysphagia, bleeding, weight loss, anemia, or hematochezia) of gastrointestinal malignancies (excluding those who did not have any endoscopically confirmed anatomical abnormalities of the esophagus or stomach); 8)Subjects with a medical history of serious hepatic, renal, neurological, respiratory, endocrine, hematological, cardiovascular, or genitourinary diseases; 9)Subjects with a history of malignancies within 5 years prior to screening (excluding those who had recovered from non-digestive malignancies for 5 years and have not relapsed); 10)Subjects with a medical history of psychiatric disorders (excluding those with psychiatric disorders who were currently stable as judged by the investigator and were not receive treatment), or drug or alcohol abuse within 12 months prior to screening; 11)Subjects who required continuous treatment with nonsteroidal anti-inflammatory drugs (e.g., aspirin), systemic glucocorticoids, and antithrombotic drugs during the study (excluding those who used low-dose aspirin [= 100 mg/day] prophylactically); 12)Subjects who were taking anti-retroviral drugs such as atazanavir and nelfinavir at screening; 13)Subjects who used therapeutic doses of drugs for gastroesophageal reflux disease within 7 days prior to randomization, such as proton pump inhibitors, potassium competitive acid blockers, histamine H2 receptor antagonists, mucosal protective drugs, drugs promoting gastrointestinal motility, and traditional Chinese medicinal products for gastroesophageal reflux disease; 14)Subjects with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin = 2 × upper limit of normal (ULN); creatinine (Scr) = 1.5 × ULN at screening; 15)Subjects who were positive for human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibodies at screening; 16)Pregnant or lactating women; subjects of childbearing potential who were unable or unwilling to use adequate contraception from the time of signing the ICF until 30 days after the last dose or their partners were unwilling to use contraception; 17)Subjects who have participated and received treatment in clinical studies of other drugs, devices, etc. within 3 months prior to screening; 18)Subjects who were ineligible (for any reason) to participate in the study as judged by the investigator.

Study Design


Intervention

Drug:
DWP14012
DWP14012 40mg

Locations

Country Name City State
China Minhu Chen Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Daewoong Pharmaceutical Co. LTD.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary mucosal healing within 8 weeks The percentage of subjects with endoscopically confirmed mucosal healing within 8 weeks. 8weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06170060 - Treatment of Reflux With Sleeve Gastrectomy N/A
Not yet recruiting NCT06062225 - Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Not yet recruiting NCT06056973 - Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis Phase 4
Completed NCT01008696 - An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Phase 4
Recruiting NCT05899491 - Role of ARMA in Selective Subset of Refractory GERD Patients. N/A
Recruiting NCT01311908 - Incidence of Reflux Esophagitis After Pancreaticoduodenectomy N/A
Completed NCT03214081 - Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Not yet recruiting NCT01560598 - Adipokines and the Risk of Reflux Esophagitis N/A
Completed NCT00859287 - Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis N/A
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Recruiting NCT04657848 - Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy N/A
Completed NCT02477475 - Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes N/A
Completed NCT03553563 - A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Phase 3
Completed NCT01381991 - The Efficacy of i-Scan for Detecting Reflux Esophagitis N/A
Completed NCT04673643 - Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis N/A
Recruiting NCT04531475 - Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis Phase 2
Completed NCT00586963 - Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis N/A
Completed NCT00634114 - Reflux Esophagitis Phase III Study (Maintenance Treatment) Phase 3
Completed NCT03388047 - Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus N/A